Three months after yet another leadership change, High Point clinical-stage pharmaceutical company vTv Therapeutics reported a slight increase in both cash position and net loss at the end of the third quarter of 2022. Paul Sekhri, who became CEO in August, told TBJ he is committed to getting the company back on the right track.
